Abstract:Background: Basophil activation contributes to inflammatory reactions, especially in allergy. It is controlled, both positively and negatively, by several mechanisms. High-affinity IgE receptors (FcεRI) generate a mixture of activation and inhibition signals when aggregated, the ratio of which depends on the concentration of allergen recognized by receptor-bound IgE. Low-affinity IgG receptors (FcγRIIA/B) generate inhibition signals when coengaged with FcεRI by allergen-antibody immune complexes. Commensal and probiotic bacteria, such as Lactobacillus paracasei, generate inhibition signals through still unclear mechanisms. Objective: We sought to investigate whether mechanisms that control, both positively and negatively, basophil activation, which were unraveled and studied in basophils from healthy donors, are functional in allergic patients. Methods: FcεRI and FcγRIIA/B expression, FcεRI-dependent activation, FcεRI-dependent inhibition, and FcγRIIB-dependent inhibition were examined in blood basophils incubated overnight with or without L paracasei and challenged under 10 experimental conditions. Basophils from healthy donors were compared with basophils from patients who consulted an allergology outpatient clinic over a period of 3 months with respiratory allergy, anaphylaxis antecedents, chronic urticaria, and/or atopic dermatitis. Results: Patients' basophils expressed neither more FcεRI nor less FcγRIIB than basophils from healthy donors. They were neither hyperreactive to positive regulation nor hyporeactive to negative regulation, irrespective of the receptors or mechanisms involved and the allergic manifestations of the patients. Conclusion: Regulatory mechanisms that control basophil activation are fully functional in allergic patients. Intrinsic defects in these mechanisms do not explain allergic manifestations. Based on these mechanisms, immune checkpoint modifiers can be developed as novel therapeutic tools for allergy.

The Expression and Function of CD300 Molecules in the Main Players of Allergic Responses: Mast Cells, Basophils and Eosinophils

The CD300 family of molecules are evolutionarily significant regulators of leukocyte functions

Immunologically mediated signaling in basophils and mast cells: finding therapeutic targets for allergic diseases in the human FcvarepsilonR1 signaling pathway.

Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways

IgG in the control of FcεRI activation: a battle on multiple fronts

The Role of Regulatory T Cells in Allergic Diseases: Collegium Internationale Allergologicum (CIA) Update 2024

Novel Approaches in the Inhibition of IgE-Induced Mast Cell Reactivity in Food Allergy

Therapeutic Targeting of the Interleukin-4/Interleukin-13 Signaling Pathway: In Allergy and Beyond

Aiming to IgE: Drug development in allergic diseases

The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets

Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing

CD300e: Emerging role and mechanism as an immune-activating receptor

Basophils from allergic patients are neither hyperresponsive to activation signals nor hyporesponsive to inhibition signals

Recent advances in cellular and molecular mechanisms of IgE-mediated food allergy

Effect of Small-Molecule Natural Compounds on Pathologic Mast Cell/Basophil Activation in Allergic Diseases

The Role of the CXCL12/CXCR4/ACKR3 Axis in Autoimmune Diseases

IgE and mast cells: The endogenous adjuvant

Lipid Ligands and Allergenic LTPs: Redefining the Paradigm of the Protein-Centered Vision in Allergy

Beyond allergic progression: From molecules to microbes as barrier modulators in the gut-lung axis functionality

Regulation of Eosinophil and Group 2 Innate Lymphoid Cell Trafficking in Asthma

Fc Receptor Targeting in the Treatment of Allergy, Autoimmune Diseases and Cancer